FDA Brief

Warning letters Drugs

FDA warning letter to

Ignacio J. Rodriguez, MD

High riskIssued Jan 29, 2021Posted Feb 9, 2021Center for Drug Evaluation and Research | CDER

FDA warns Dr. Ignacio J. Rodriguez for enrolling ineligible subjects and giving study drug without required checks in a clinical trial.

What happened

FDA inspected Dr. Rodriguez's clinical site between August 18 and September 29, 2020, and reviewed records and his October 20, 2020 response. FDA found that he enrolled and randomized subjects who met exclusion criteria, randomized subjects without required randomization criteria, and gave study drug without required assessments or central reviewer confirmation. FDA said these failures jeopardized subject safety and the validity of the data.

What FDA found

  1. Failed to ensure the clinical investigation was conducted according to the investigational plan.

    21 CFR 312.60
  2. Enrolled and randomized subjects who had conditions that the protocol required be excluded.

    21 CFR 312.60
  3. Randomized subjects without meeting required randomization criteria, including required prior tests and calls into the study's randomization system.

    21 CFR 312.60
  4. Administered study drug without required assessments or before the central reviewer confirmed eligibility.

    21 CFR 312.60

What FDA wants

Within 15 days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations. If you believe you complied, include your reasoning and supporting information.

Who should pay attention

  • sponsors and CROs relying on clinical site data
  • other clinical investigators and site staff
  • IRBs overseeing drug trials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  3. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  4. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk